AHEAD OF PRINT
Cover
RJPS Vol No: 15 Issue No: 1 eISSN: pISSN:2249-2208
Article Submission Guidelines
Dear Authors,
We invite you to watch this comprehensive video guide on the process of submitting your article online. This video will provide you with step-by-step instructions to ensure a smooth and successful submission.
Thank you for your attention and cooperation.
RP-HPLC Method Development and Validation of Labetalol HCl for bulk and Pharmaceutical Formulation
Namratha NY, DeviReddy Prashanthi*, Chaithanya MS, Veeresh Prabhakar Veerapur
Department of Pharmaceutical Quality Assurance, Sree Siddaganga College of Pharmacy, Tumkur-572 103, Karnataka, India
Objective: To develop an easy, efficient and rapid analytical technique for the development and validation of Labetalol in dosage forms. Methods: The drug was eluted isocratically using a Shimpack (C18, 4.6 x 250 mm, 5μm) column in mode, using Acetonitrile and Phosphate buffer pH 6.5 (60:40 v/v) at 1 mL/min, with 306 nm as detection wavelength at 3.3 min Results: This method showed a linear response for concentrations 10 to 50 μg/mL with 0.9998 as correlation coefficient. The current method was validated in terms of system suitability, specificity, linearity, precision, accuracy, LOD (Limit of detec tion), LOQ (Limit of quantification) and robustness. The recovery of Labetalol HCl was found to be 101.26%. The percentage assay of Labetalol HCl present in the marketed formulation (Labebet-100 mg) was found to be 102.34%. Conclusion: Thus, this proposed method can be successfully executed for the routine analytical work of Labeta lol HCl in bulk and tablet dosage forms, in accordance with ICH Q2 R1 guidelines.
Anti-Atherosclerotic Activity of Plumeria Acuminata Leaf Extract Against Triton X-100 Induced Hyperlipidemia Model in Rats
Mounika G S*, Rajesh M S
Department of Pharmacology, Government College of Pharmacy, Sampangiramnagar, Bengaluru, Karnataka, India
Background: Hyperlipidemia, characterized by elevated levels of lipids in the blood, is a significant risk factor for cardiovascular diseases, including atherosclerosis. This study explains the potential effects of the methanol extract of Plumeria acuminata leaves against atherosclerosis. Objective: Nine formulations of mucoadhesive microspheres were created, incorporating Carbopol-934P and different ratios of AIFM. A central composite design was employed using Design-Expert software to assess the influence of independent variables (concentrations of polymers) on the dependent variable (mucoadhesive strength). The microspheres underwent compatibility studies and various physical evaluations, including analysis of Acyclovir content and its discharge kinetics. Methods: Anti-atherosclerotic activity of Plumeria acuminata was evaluated on Triton X-100 induced hyperlipidemia in rats by measuring levels of biochemical serum parameters and histopathological assessment. Results: The in-vivo anti-atherosclerotic activity of different doses (100, 200, 400 mg/kg) of methanol extract of Plumeria acuminata leaves was carried out against Triton X-100 induced hyperlipidemia model. During the study, it was found that the methanol extract of Plumeria acuminata leaves (MEPAL) resulted in significant (P< 0.001) decrease in the biochemical serum parameters such as ALT, AST, ALP, total cholesterol, Triglycerides, LDL-Cholesterol, HDL-Cholesterol, LDH, VLDL-Cholesterol, CPK and FFA levels as compared to disease control groups and these findings were further supported with histopathological studies. Thus, the present finding provides scientific evidence of ethnomedical value of Plumeria acuminata leaves in cardiovascular diseases. Conclusion: Methanolic extract of Plumeria acuminata leaves possess a significant anti-atherosclerotic activity against Triton X-100 induced hyperlipidemia in Albino Wistar rats.
Synthesis, Characteriztion and Antimicrobial Activities of Novel Pyrrolyl Benzimidazole Derivatives
Vidya Kamatar, Soumya N. Irappannavar, Channabasappa S. Hallikeri * , Shrinivas D. Joshi
Department of Pharmaceutical Chemistry, Novel Drug Design and Discovery Laboratory, S.E.T’s College of Pharmacy, Sangolli Rayanna Nagar, Dharwad, Karnataka, India
Background Tuberculosis (TB) is a deadly disease caused by Mycobacterium tuberculosis complex. Most of the TB drugs are pretty old and were developed more than 40 years ago. There will be an estimation of 1.3 million multi-drug resistant TB. Due to this increased microbial resistance, new classes of antimicrobial agents with novel mechanisms are needed today to fight against the multi-drug resistant infections. Objectives Development and standardization of the methods to synthesize the new pyrrolyl benzimidazole derivatives. Synthesized derivatives were characterized by different analytical techniques such as IR, 1HNMR, 13CNMR, mass spectral data, and all compounds screened for antitubercular and antibacterial activities. Methodology Pyrrolyl benzimidazole series were prepared by refluxing substituted orthophenylenediamine (1) and para-aminobenzoic acid (2) with ethanol for 8 h. and, 10% of NaOH solution was added to obtained substituted-(1H-benzo (d) imidazole-2-yl) aniline (3a-d). This was treated with 2,5-dimethoxy tetrahydrofuran in glacial acetic acid and refluxed for 30 mins to get substituted 2-(4-(1H-pyrrol-1-yl) phenyl)-1H-benzo[d]imidazole (4 a-d) further these (3a-d) were refluxed with acetonyl acetone in glacial acetic acid to get 4- substituted 2-(4-(2,5-dimethyl-1H-pyrrol-1-yl) phenyl)-1H-benzo[d]imidazole (5a-d). The mixture was filtered and dried. Recrystallized from ethanol and obtained as brown crystals. Results Synthesized derivatives with a melting point of 286-290 °C. Results indicate compounds exhibit antibacterial activity (expressed as MIC) in the range of 6.25 to 100 µg/mL against gram-positive and gram-negative bacteria. Compounds 4d and 5d showed significant antibacterial activity at MIC value 3.12 µg/mL, and compounds 4c and 5c showed antitubercular activity at MIC value 6.25 µg/mL. Conclusion These compounds can be further modified to get more potent antibacterial and antitubercular agents.